MYMD vs. NAVB, BMRA, TRIB, CDIO, OCX, XBIO, HOTH, HCTI, AVGR, and KTRA
Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Biomerica (BMRA), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), OncoCyte (OCX), Xenetic Biosciences (XBIO), Hoth Therapeutics (HOTH), Healthcare Triangle (HCTI), Avinger (AVGR), and Kintara Therapeutics (KTRA). These companies are all part of the "medical" sector.
MyMD Pharmaceuticals (NASDAQ:MYMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
Navidea Biopharmaceuticals' return on equity of 0.00% beat MyMD Pharmaceuticals' return on equity.
MyMD Pharmaceuticals and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users.
MyMD Pharmaceuticals has higher earnings, but lower revenue than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, MyMD Pharmaceuticals had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for MyMD Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 1.44 beat Navidea Biopharmaceuticals' score of 0.00 indicating that MyMD Pharmaceuticals is being referred to more favorably in the media.
MyMD Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
9.6% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.6% of MyMD Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get MyMD Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyMD Pharmaceuticals Competitors List
Related Companies and Tools
